Immuno-oncology Approaches in Uveal Melanoma: Tebentafusp and Beyond

Overview

Journal Immunooncol Technol

Specialty Allergy & Immunology

Date 2023 Jul 24

PMID 37483658

Authors

C Gerard

B Shum

P Nathan

S Turajlic

Affiliations

Soon will be listed here.

Abstract

Uveal melanoma (UM) is the most common ocular malignancy in adults, associated with the poorest prognosis, with metastatic disease occurring in up to 50% of patients. In contrast to metastatic cutaneous melanoma, the use of immune checkpoint inhibitors is associated with poor outcomes in metastatic uveal melanoma (mUM). Tebentafusp, a bispecific molecule, has recently become the first treatment in decades to improve overall survival for mUM. This review summarises the existing and emerging immuno-oncology approaches for the treatment of mUM, and biomarkers of response and resistance to the same. Finally, we propose future research directions that could maximise treatment benefit to a wider pool of patients with UM.

Citing Articles

Optimizing ctDNA: An Updated Review of a Promising Clinical Tool for the Management of Uveal Melanoma.

Varela M, Villatoro S, Lorenzo D, Piulats J, Caminal J Cancers (Basel). 2024; 16(17).

PMID: 39272911 PMC: 11394595. DOI: 10.3390/cancers16173053.

References

Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel K, Becher R . Prognostic implications of monosomy 3 in uveal melanoma. Lancet. 1996; 347(9010):1222-5. DOI: 10.1016/s0140-6736(96)90736-9. View

Lalonde E, Ewens K, Richards-Yutz J, Ebrahimzedeh J, Mizue Terai , Gonsalves C . Improved Uveal Melanoma Copy Number Subtypes Including an Ultra-High-Risk Group. Ophthalmol Sci. 2022; 2(2):100121. PMC: 9559896. DOI: 10.1016/j.xops.2022.100121. View

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J, Rutkowski P, Lao C . Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019; 381(16):1535-1546. DOI: 10.1056/NEJMoa1910836. View

Whelchel J, Farah S, McLean I, Burnier M . Immunohistochemistry of infiltrating lymphocytes in uveal malignant melanoma. Invest Ophthalmol Vis Sci. 1993; 34(8):2603-6. View

Tawbi H, Schadendorf D, Lipson E, Ascierto P, Matamala L, Castillo Gutierrez E . Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022; 386(1):24-34. PMC: 9844513. DOI: 10.1056/NEJMoa2109970. View

Stalhammar G, Seregard S, Grossniklaus H . Expression of immune checkpoint receptors Indoleamine 2,3-dioxygenase and T cell Ig and ITIM domain in metastatic versus nonmetastatic choroidal melanoma. Cancer Med. 2019; 8(6):2784-2792. PMC: 6558646. DOI: 10.1002/cam4.2167. View

Topper M, Vaz M, Marrone K, Brahmer J, Baylin S . The emerging role of epigenetic therapeutics in immuno-oncology. Nat Rev Clin Oncol. 2019; 17(2):75-90. PMC: 7254932. DOI: 10.1038/s41571-019-0266-5. View

Hoefsmit E, Rozeman E, Van T, Dimitriadis P, Krijgsman O, Conway J . Comprehensive analysis of cutaneous and uveal melanoma liver metastases. J Immunother Cancer. 2020; 8(2). PMC: 7713183. DOI: 10.1136/jitc-2020-001501. View

Souri Z, Jochemsen A, Versluis M, Wierenga A, Nemati F, van der Velden P . HDAC Inhibition Increases HLA Class I Expression in Uveal Melanoma. Cancers (Basel). 2020; 12(12). PMC: 7763827. DOI: 10.3390/cancers12123690. View

10.

Furney S, Pedersen M, Gentien D, Dumont A, Rapinat A, Desjardins L . SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov. 2013; 3(10):1122-1129. PMC: 5321577. DOI: 10.1158/2159-8290.CD-13-0330. View

11.

Van Raamsdonk C, Griewank K, Crosby M, Garrido M, Vemula S, Wiesner T . Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010; 363(23):2191-9. PMC: 3107972. DOI: 10.1056/NEJMoa1000584. View

12.

Algazi A, Tsai K, Shoushtari A, Munhoz R, Eroglu Z, Piulats J . Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016; 122(21):3344-3353. PMC: 5767160. DOI: 10.1002/cncr.30258. View

13.

Hamid O, Hassel J, Shoushtari A, Meier F, Bauer T, Salama A . Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study. J Immunother Cancer. 2023; 11(6). PMC: 10254987. DOI: 10.1136/jitc-2023-006747. View

14.

Makitie T, Summanen P, Tarkkanen A, Kivela T . Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2001; 42(7):1414-21. View

15.

Tosi A, Cappellesso R, Dei Tos A, Rossi V, Aliberti C, Pigozzo J . The immune cell landscape of metastatic uveal melanoma correlates with overall survival. J Exp Clin Cancer Res. 2021; 40(1):154. PMC: 8097926. DOI: 10.1186/s13046-021-01947-1. View

16.

Figueiredo C, Kalirai H, Sacco J, Azevedo R, Duckworth A, Slupsky J . Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development. J Pathol. 2020; 250(4):420-439. PMC: 7216965. DOI: 10.1002/path.5384. View

17.

Johansson P, Stark A, Palmer J, Bigby K, Brooks K, Rolfe O . Prolonged stable disease in a uveal melanoma patient with germline MBD4 nonsense mutation treated with pembrolizumab and ipilimumab. Immunogenetics. 2019; 71(5-6):433-436. DOI: 10.1007/s00251-019-01108-x. View

18.

Diener-West M, Reynolds S, Agugliaro D, Caldwell R, Cumming K, Earle J . Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol. 2005; 123(12):1639-43. DOI: 10.1001/archopht.123.12.1639. View

19.

Madic J, Piperno-Neumann S, Servois V, Rampanou A, Milder M, Trouiller B . Pyrophosphorolysis-activated polymerization detects circulating tumor DNA in metastatic uveal melanoma. Clin Cancer Res. 2012; 18(14):3934-41. DOI: 10.1158/1078-0432.CCR-12-0309. View

20.

Karlsson J, Nilsson L, Mitra S, Alsen S, Shelke G, Sah V . Molecular profiling of driver events in metastatic uveal melanoma. Nat Commun. 2020; 11(1):1894. PMC: 7171146. DOI: 10.1038/s41467-020-15606-0. View